FDA approves Roche Tecentriq combination therapy for NSCLC patients

234,000 newly diagnosed lung cancer cases in the United States in 2018, according to estimates by the American Cancer SocietyLung cancer can be divided into two categories, non-small cell lung cancer and small cell lung cancerNon-small cell lung cancer accounts for 85% of the total number of lung cancertoday, Roche's Genentechcompany,(http:// announcedthat the U.SFDA(http://approved the company's Tecentriq and casolizumab, a combination of yew alcohol and catechol (ABCP) as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC)tumors in these patients do not carry the EGFR/ALK gene variantThe FDA yesterday granted Tecentriq priority review for the treatment of widespread small cell lung cancer (ES-SCLC)This means that tecentriq-based combination therapies are expected to benefit more lung cancer patientstecentriq
Tecentriq is an anti-PD-L1 antibody developed by Roche that, by blocking PD-L1 in combination with PD-1 and B7.1 receptors, can reactivate T cells, prompting them to kill tumor cellsTecentriq has received FDA approval as a second-line therapy for patients with metastatic non-small cell lung cancer (NSCLC)This approval will further expand the patient population for the treatment the results of the of the study are based on the of the Phase 3 Clinical Trial (http:// called IMpower150 In this study, NSCLC patients were treated with ABCP combination therapy, or bevan monoantigen and chemotherapy-consisting combination therapy (BCP) results showed that ABCP combination therapy reduced the risk of death by 22 percent compared to BCP therapy in the wild-type intent therapy (ITT-WT) patient population The median total lifetime (OS) in patients in the ABCP group was 19.2 months, significantly better than that of 14.7 months in the BCP group (HR-0.78; 95% CI: 0.64-0.96; p-0.016)